Parmar Kalpesh, Hanson Mark, Mahrous Ahmed S, Keeley Francis X, Timoney Anthony G, Albuheissi Salah, Rai Bhavan Prasad, Philip Joe
Freeman Hospital, Newcastle, UK.
Bristol Urological Institute, Southmead Hospital, Westbury-On-Trym, Bristol, BS10 5NB, UK.
World J Urol. 2024 Feb 10;42(1):76. doi: 10.1007/s00345-023-04734-z.
Upper urinary tract urothelial cancer is a rare, aggressive variant of urinary tract cancer. There is often delay to diagnosis and management for this entity in view of diagnostic and staging challenges needing additional investigations and risk stratifications for improved outcomes. In this article, we share our experience in developing a dedicated diagnostic and treatment pathway for UTUC and assess its impact on time lines to radical nephroureterectomy (RNU). We also evaluate the impact of diagnostic ureteroscopy (DUR) on UTUC care pathways timelines.
A prospective database was maintained for all patients who underwent a RNU from January 2015 to August 2022 in a high-volume single tertiary care centre in the UK. In 2019, a Focused UTUC pathway (FUP) was implemented at the centre to streamline diagnostic and RNU pathways. A retrospective analysis of the database was conducted to compare time lines and diagnostic trends between the pre-FUP and FUP cohorts. Primary outcome measures were time to RNU from MDT. Secondary outcome measures were: impact of DUR on time to RNU from MDT and negative UTUC rates between DUR and non-DUR cohorts. Differences in continuous variables across categories were assessed using the independent sample t test. Categorical variables between cohorts were analysed using the chi-square (χ). Statistical significance in this study was set as p < 0.05.
A total of 500 patients with complete data were included in the analysis. The pre-FUP and FUP cohorts consisted of 313 patients and 187 patients, respectively. The overall cohort had a mean age (SD) of 70 years (9.3). 66% of the overall cohort were males. The median time to RNU from MDT in the FUP was significantly lower compared to the pre-FUP cohort; 62 days (IQR 59) vs. 48 days (IQR 41.5), p < 0.0001. The median time to RNU from MDT in patients who underwent a diagnostic URS in the FUP cohort was significantly lower compared to the pre-FUP cohort; 78.5 days (IQR 54.8) vs. 68 days (IQR 48), p-NS. The non-UTUC rates in the DUR and non-DUR cohorts were 6/248 (2.4%) and 14/251 (5.6%), respectively (NS).
In this series, we illustrate the effectiveness of integrating a multidisciplinary approach with specialised personnel, ring-fenced clinics, efficient diagnostic assessment and optimised theatre capacity. By adopting a risk-stratified approach to diagnostic ureteroscopy, we have achieved a significant reduction in time to RNU.
上尿路尿路上皮癌是一种罕见的侵袭性尿路癌。鉴于诊断和分期面临挑战,需要进行额外检查和风险分层以改善治疗效果,因此该疾病的诊断和治疗常常会延迟。在本文中,我们分享了我们在制定专门的上尿路尿路上皮癌诊断和治疗路径方面的经验,并评估其对根治性肾输尿管切除术(RNU)时间线的影响。我们还评估了诊断性输尿管镜检查(DUR)对上尿路尿路上皮癌治疗路径时间线的影响。
在英国一家大型单一三级医疗中心,对2015年1月至2022年8月期间接受RNU的所有患者维护了一个前瞻性数据库。2019年,该中心实施了聚焦上尿路尿路上皮癌路径(FUP),以简化诊断和RNU路径。对数据库进行回顾性分析,以比较FUP前和FUP队列之间的时间线和诊断趋势。主要结局指标是从多学科团队(MDT)到RNU的时间。次要结局指标是:DUR对从MDT到RNU时间的影响以及DUR和非DUR队列之间的阴性上尿路尿路上皮癌发生率。使用独立样本t检验评估不同类别连续变量的差异。队列之间的分类变量使用卡方(χ)分析。本研究中的统计学显著性设定为p < 0.05。
共有500例具有完整数据的患者纳入分析。FUP前和FUP队列分别由313例患者和187例患者组成。整个队列的平均年龄(标准差)为70岁(9.3)。整个队列中66%为男性。与FUP前队列相比,FUP中从MDT到RNU的中位时间显著缩短;62天(四分位间距59)对48天(四分位间距41.5),p < 0.0001。FUP队列中接受诊断性输尿管软镜检查(URS)的患者从MDT到RNU的中位时间与FUP前队列相比显著缩短;78.5天(四分位间距54.8)对68天(四分位间距48),p无统计学意义。DUR和非DUR队列中的非上尿路尿路上皮癌发生率分别为6/248(2.4%)和14/251(5.6%)(无统计学意义)。
在本系列研究中,我们展示了将多学科方法与专业人员、专用诊所、高效诊断评估和优化的手术能力相结合的有效性。通过采用风险分层的诊断性输尿管镜检查方法,我们显著缩短了至RNU的时间。